Business Wire

CA-MFA

7.9.2022 14:01:51 CEST | Business Wire | Press release

Share
MFA Delivers New Tools for Enterprises to Simplify Their Private Network Deployments

MFA, the industry Alliance supporting private network adoption, today announced that it is launching a new resource center on its website for enterprises to gain access to tools that will aid their 3GPP-based private network deployments and to highlight private networks globally. Enterprises can access these tools to simplify their own private network deployments and to learn about available spectrum options in their region.

“The connectivity requirements of enterprises are becoming more complex, with thousands of devices on a network conducting business-critical applications,” said Mazen Chmaytelli, president, MFA. “MFA is a leading industry resource for enterprises looking to understand the benefits and opportunities of 3GPP-based private networks for their business. Our mission is to make it as easy as possible for enterprises to deploy their own private network in any spectrum, and we are providing the tools and resources to help them facilitate that and achieve their digitalization goals.”

As part of its new private networks resource center, MFA is launching a private network tracker in partnership with industry analyst firm, Mobile Experts. The tracker provides insight into the state of private networks across various industry verticals and enterprises as well as regions where private networks are gaining ground.

“As of the end of June 2022, Mobile Experts estimates that more than 2,800 private LTE and 5G networks have been cumulatively deployed,” said Kyung Mun, principal analyst, Mobile Experts. “We also forecast that the private cellular equipment market will grow 12-15% this year to $1.9B and continue to ramp as the industrial device ecosystem scales. We also see that additional regulators are taking their cue from early actions in Germany, Japan, USA and the UK to make available dedicated private 5G spectrum. MFA will be providing ongoing updates on private network deployments globally so enterprises can learn about trends and best practices.”

New monthly newsletter
Enterprises are encouraged to subscribe to MFA’s new newsletter that will feature a monthly update on private networks deployed globally in a variety of industries, as well as feature new white papers, case studies, and resources. Subscribe at www.mfa-tech.org/newsletter.

Uni5G Technology Blueprints available for enterprises
MFA has also made its Uni5G™ Technology Blueprints publicly available for any enterprise to download. The blueprints leverage 3GPP 5G standards to define profiling and classification requirements for private networks. Enterprises can use the blueprints as a tool with their vendor of choice to let them know which select features their devices need to implement. The initial set of blueprints is based on 3GPP Release 15, and the next set of blueprints based on Release 16 and beyond are under development.

Meet us at Hannover Messe USA
MFA will be presenting at Hannover Messe USA in the Solutions Theater located in Building 1, Level 3.

  • Monday, Sept. 12, 10:30-11:00AM: Practical Tools to Simplify Your Private Network Deployment by Mazen Chmaytelli, MFA President
  • Friday, Sept. 16, 11:15-11:45AM: Deploying a Private 5G Network Doesn’t have to be Rocket Science by Asimakis Kokkos, MFA Technical Specification Group Chair

MFA representatives will also showcase technology solutions and resources in Booth #134661. To schedule a meeting with MFA’s private network experts, contact press@mfa-tech.org.

Resources:

About MFA
MFA is an industry Alliance supporting private network adoption. We provide resources that simplify the path to optimized, reliable and secure private networks in locally licensed, shared, or unlicensed spectrum. MFA enables the ecosystem with its free Uni5G™ Technology Blueprints and its unique global PLMN-ID program. Uni5G, based on 3GPP specifications, identifies the key 5G features needed for enterprises to successfully deploy their own private network. MFA is a 3GPP Market Representation Partner. Learn more at www.mfa-tech.org.

Become an MFA member
Join MFA as a contributor or an adopter member to participate in working groups, receive complimentary access to MFA’s Private Network Identifier packages, and to augment your company’s marketing activities. Learn more at Join | MFA (mfa-tech.org).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005526/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye